Small-cell carcinoma

Global Non-Small Cell Lung Cancer Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Monday, January 18, 2021 - 8:50am

The "Global Non-Small Cell Lung Cancer Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Small Cell Lung Cancer Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Non-Small Cell Lung Cancer Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Non-Small Cell Lung Cancer market.
  • It covers emerging therapies for Non-Small Cell Lung Cancer in active clinical development stages including early and late stage clinical trials.
  • The report provides Non-Small Cell Lung Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

Thursday, January 14, 2021 - 4:00am

This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

Key Points: 
  • This is the third approval in China for tislelizumab, and its first in a lung cancer indication.
  • Tislelizumab is being investigated in a broad clinical program, including five Phase 3 trials in lung cancer indications.
  • We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer, said Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
  • The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com

Tuesday, January 12, 2021 - 12:47pm

The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • Of total lung cancer incident cases, approximately 85% are the NSCLC subtype.
  • Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting.

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.

Monday, January 11, 2021 - 3:03am

The submission has been accepted by the Center of Drug Evaluation of the NMPA.

Key Points: 
  • The submission has been accepted by the Center of Drug Evaluation of the NMPA.
  • The population of SCLC patients account for about 15-20% of all lung cancer patients.
  • For the moment, the main clinical treatment methods of SCLC are radiotherapy and chemotherapy, which may only have short-term effect, and the disease is easy to relapse.
  • This also lays a good start for the further development of Chiauranib, which is the third original innovative drug discovered and developed by Chipscreen.

Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

Tuesday, January 5, 2021 - 6:00am

Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomized data from the Phase II CITYSCAPE trial.

Key Points: 
  • Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomized data from the Phase II CITYSCAPE trial.
  • Tiragolumab is also being investigated in metastatic esophageal squamous cancer (SKYSCRAPER-08) and cervical cancer (SKYSCRAPER-04), with early trials in other tumor types.
  • Blocking both pathways simultaneously with tiragolumab and Tecentriq has the potential to increase anti-tumor activity by enhancing the bodys immune response to cancer cells.
  • CITYSCAPE is a global Phase II, randomized and blinded study evaluating tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone in 135 patients with first-line PD-L1-positive, locally advanced unresectable or metastatic non-small cell lung cancer.

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Monday, January 4, 2021 - 12:30pm

Treatment options for small cell lung cancer are limited, as are options for other DLL3-associated tumors such as neuroendocrine prostate cancer.

Key Points: 
  • Treatment options for small cell lung cancer are limited, as are options for other DLL3-associated tumors such as neuroendocrine prostate cancer.
  • We are excited to participate in this trial of a promising agent that will hopefully benefit patients with small cell lung cancer and other neuroendocrine tumors, said Melissa Johnson, M.D., Program Director of Lung Cancer Research at Sarah Cannon Research Institute.
  • HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors.
  • These forward-looking statements are based on Harpoon Therapeutics expectations and assumptions as of the date of this press release.

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...

Monday, November 9, 2020 - 9:10pm

KEYTRUDA monotherapy remains a standard of care for the treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.

Key Points: 
  • KEYTRUDA monotherapy remains a standard of care for the treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.
  • Merck has an extensive clinical development program in lung cancer and is advancing multiple registration-enabling studies with KEYTRUDA in combination with other treatments and as monotherapy.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Monday, November 9, 2020 - 1:00pm

At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points: 
  • At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
  • Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to anti-PD-1 therapies currently available.
  • A copy of the poster presentation is available on the Publications page of the Pipeline section of Checkpoints website, www.checkpointtx.com .
  • According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2020, and non-small cell lung cancer accounts for 80-85% of all lung cancers.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Friday, November 6, 2020 - 11:59am

The combination of Opdivo plus Yervoy has previously demonstrated long-term survival outcomes across multiple cancer types, including melanoma and renal cell carcinoma.

Key Points: 
  • The combination of Opdivo plus Yervoy has previously demonstrated long-term survival outcomes across multiple cancer types, including melanoma and renal cell carcinoma.
  • We are pleased to see new treatment options approved that may potentially help more people with metastatic non-small cell lung cancer.''
  • ORR was significantly higher for Opdivo plus Yervoy with two cycles of chemotherapy vs. chemotherapy alone: 38% vs. 25% (p=0.0003).
  • Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 84% of diagnoses.

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Thursday, October 29, 2020 - 12:16pm

We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.

Key Points: 
  • We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.
  • Final approval of the REQORSA brand name is conditional on FDA approval of the product candidate.
  • In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZenecas Tagrisso for the treatment of non-small cell lung cancer.
  • The Companys lead product candidate, REQORSA immunogene therapy drug (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).